Obesity Clinical Trial
Official title:
Timing of Sodium Intake and Nocturnal Sodium Excretion and Blood Pressure in Obese
Experimental data have shown that timing of sodium intake impacts diurnal patterns of sodium excretion. The purpose of this study is to test the hypothesis that the time of day for salt intake impacts (1) blood pressure rhythms and urinary sodium excretion and (2) circadian timing of factors responsible for blood pressure regulation and cardiometabolic health in obese individuals. These studies will address two aims. The first aim will test the hypothesis that limiting high salt intake prior to sleep increases day-night differences in blood pressure, improves timing of urinary sodium excretion, and improves metabolic risk factors. The second aim will test the hypothesis that limiting high salt intake prior to sleep preferentially improves rhythmicity in peripheral vs. central circadian clock factors linked to renal sodium handling. The proposed hypothesis-driven studies will determine how timing of sodium intake affects diurnal blood pressure and circadian timing of factors responsible for blood pressure control and metabolic health, with the ultimate goal of identifying novel strategies to treat nocturnal hypertension and metabolic disease in obesity.
Status | Recruiting |
Enrollment | 55 |
Est. completion date | September 30, 2025 |
Est. primary completion date | July 31, 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 25 Years to 45 Years |
Eligibility | Inclusion Criteria: - obese (BMI 30-50 kg/m2) - 25-45 years of age Exclusion Criteria: - evidence of kidney disease (eGFR < 60 ml/min/1.73m2 or abnormal urinalysis) - elevated BP (>150/90 mmHg [measured at screening in duplicate after 10min lying recumbent]) - elevated fasting glucose (>126 g/dL on screening labs) - severe anemia (hemoglobin < 8 g/dL for women or < 9 g/dL for men) - significant psychiatric illness (as assessed by a validated screening form) - past or present drug or alcohol abuse (drug screen) - taking 2 or more BP medications or supplements on a regular basis - alcohol intake more than 2 drinks/day - pregnancy - women taking hormone replacement therapy, or post-menopausal women; - shift worker - sleep disorders (such as sleep apnea assessed by Apnea Link) - major chronic disease (e.g., diabetes, lymphocyte disorders) - history of smoking or use of tobacco products within the past year - use of sleep medications, hypnotics, stimulants, or anti-depressants |
Country | Name | City | State |
---|---|---|---|
United States | University of Alabama | Birmingham | Alabama |
Lead Sponsor | Collaborator |
---|---|
University of Alabama at Birmingham |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 24-hour blood pressure | Difference in nocturnal blood pressure between study arms | 7 days | |
Primary | Core Body Temperature | Difference in core body temperature between study arms | 7 days | |
Primary | Timing of plasma melatonin increase under dim-light conditions (dim-light melatonin onset) | Difference in the rise of plasma melatonin during the night under dim-light conditions between study arms | 8 days | |
Secondary | 24-hour urinary sodium excretion | Difference in day-night urinary sodium excretion between study arms | 8 days | |
Secondary | Buccal cell clock gene expression (CLOCK, Bmal1, per1, per2, Rev-erb-alpha, cry1, cry2) | Difference in buccal cell clock gene expression (CLOCK, Bmal1, per1, per2, Rev-erb-alpha, cry1, cry2) between study arms. Measures of clock gene expression will all be analyzed as fold change from baseline. | 8 days | |
Secondary | Concentrations of plasma melatonin | Difference in plasma melatonin concentrations between study arms | 8 days | |
Secondary | Concentrations of plasma cortisol | Difference in plasma cortisol concentrations between study arms | 8 days | |
Secondary | Peripheral blood monocyte clock gene (CLOCK, Bmal1, per1, per2, Rev-erb-alpha, cry1, cry2) expression | Difference in peripheral blood monocyte clock gene ((CLOCK, Bmal1, per1, per2, Rev-erb-alpha, cry1, cry2)) expression between study arms. Measures of clock gene expression will all be analyzed as fold change from baseline. | 8 days | |
Secondary | Flow cytometric analysis of circulating immune cells (CD3+, CD4+, CD8+, CD14+, CD45+) | Difference in flow cytometric analysis of circulating immune cells (CD3+, CD4+, CD8+, CD14+, CD45+) between study arms. All flow cytometric analyses will be analyzed as percentage of total nucleated cells. | 8 days | |
Secondary | Concentrations of plasma and urine endothelin 1 | Difference in plasma and urine endothelin 1 concentrations between study arms | 8 days | |
Secondary | Concentrations of plasma and urine aldosterone | Difference in plasma and urine aldosterone concentrations between study arms | 8 days | |
Secondary | Concentrations of plasma vasopressin | Difference in plasma vasopressin concentrations between study arms | 8 days | |
Secondary | Concentrations of plasma cytokine (TNA-alpha, IL-1, IL-6, IL-12, IL-17, IL-18, IL-23, IL-10, TGB-beta) | Difference in plasma cytokine measures ((TNA-alpha, IL-1, IL-6, IL-12, IL-17, IL-18, IL-23, IL-10, TGB-beta) between study arms. All cytokine measurements will be analyzed as pg/ml. | 8 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |